Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890338 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06890338: Recruiting Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AbbVie.
NCT06890338 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 140 participants, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06890338, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Primary Outcome
OR is defined as the best overall response of radiographic complete response (CR) or partial response (PR) as assessed by ICR using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including interval debulking surgery (IDS).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Mirvetuximab Soravtansine
Study Locations (20)
California
- Scripps Mercy Hospital /ID# 276891 - San Diego
- California Pacific Medical Center /ID# 275329 - San Francisco
- Ridley Tree Cancer Center /ID# 275219 - Santa Barbara
Louisiana
- Women'S Cancer Care /ID# 276469 - Covington
- University Medical Center New Orleans /ID# 274755 - New Orleans
- Trials 365 /ID# 274310 - Shreveport
Alabama
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793 - Birmingham
- Usa Mitchell Cancer Institute /ID# 276022 - Mobile
Connecticut
- Danbury Hospital, Western Connecticut Health Network /ID# 274783 - Danbury
- Norwalk Hospital /ID# 274561 - Norwalk
Florida
- Jupiter Medical Center /ID# 276616 - Jupiter
- Mount Sinai Medical Center /ID# 274868 - Miami
Illinois
- Rush Md Anderson Cancer Center /ID# 274926 - Chicago
- OSF St. Francis Medical Center /ID# 274752 - Peoria
Indiana
- Parkview Research Center /ID# 274338 - Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492 - Indianapolis
Kentucky
- Baptist Health Lexington /ID# 275218 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
What NCT06890338 shows while recruiting
NCT06890338 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (45% lower).
The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06890338 names 20 study sites across 11 states, led by California, Louisiana, Alabama.
Frequently Asked Questions
What is clinical trial NCT06890338 about?
NCT06890338 is a clinical study titled "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous e...
What is the current status of trial NCT06890338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-11-21. Estimated completion is 2030-02.
What conditions does trial NCT06890338 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Neoadjuvant.
What interventions are being tested in trial NCT06890338?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Mirvetuximab Soravtansine (DRUG).
Who is sponsoring clinical trial NCT06890338?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06890338 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06890338's enrollment target sits among peer trials
140 26th of 85 higher than 59 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI